Hyperlipidaemia in pregnancy

Česká verzia

Authors: Z. Kokrdová; M. Košťál
Authors place of work: Fakulta zdravotnických studií, Univerzita Pardubice, děkan prof. MUDr. A. Pellant, DrSc. ; Gynekologicko-porodnická klinika, Pardubická krajská nemocnice, a. s., přednosta doc. MUDr. M. Košťál, CSc.
Published in the journal: Ceska Gynekol 2013; 78(2): 150-156

Summary

Objective:
We investigated the degree of pregnancy - induced hyperlipidaemia in normal and complicated pregnancies. Under the „stress of pregnancy“ supraphysiologic increase in lipid and lipoprotein levels may delevop (similar to changes in carbohydrate metabolism).

Design:
Clinical study.

Setting:
Department of Obstetrics and Gynaecology, Regional Hospital Pardubice, Faculty of Health Studies, University of Pardubice.

Methods:
Fasting plasma lipid and lipoprotein levels were studied in 26 healthy pregnant women, in 30 women with high risk pregnancy and in 30 nonpregnant healthy controls. The results were compared to reference values given in percentiles to find those exceeding the 95th percentile of the reference values for the third trimester.

Results:
Two subjects (3.6%) with supraphysiologic increase in plasma lipids in late pregnancy were identified among the 56 women studied. The details are reviewed in the study as well as the rare forms of extreme hyperlipoproteinaemia during pregnancy in women with pre-existing disorder of lipid metabolism.

Conclusion:
The measurement of lipid and lipoprotein levels cannot be recommended in all pregnant women in late pregnancy. Hovewer, in subjects with family history of dyslipidaemia or premature atherosclerosis in the first - degree relatives and without hyperlipidaemia outside pregnancy, supraphysiologic increase in lipid and lipoprotein levels developed under the „stress of pregnancy“ might indentify women at risk of dysli-pidaemia in future life.

Keywords:
supraphysiologic hyperlipidaemia – lipid disorders – pregnancy

Zdroje

1. Anedda, S., Mura, S., Marcello, C., Pitus, P. Help LDL-apheresis in two cases of familial hypecholesterolemic pregnant women. Transfus Apher Sci, 2011, 44(1), p. 21–24.

2. Barker, DJP. Fetal programming of coronary heart disease. Trends Endocrinol Metab, 2002, 19(9), p. 364–368.

3. Basaran, A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci, 2009, 16(5), p. 431–437.

4. Ben-Haroush, A., Yogev, Y., Hod, M. Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med, 2004, 21, p. 103–113.

5. Butte, NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr, 2000, 71, p. 1256S–1261S.

6. Eapen, DJ., Valiani, K., Reddy, S., Sperling, L. Management of familial hypercholesterolemia during pregnancy: case series and discussion. J Clin Lipidol, 2012, 6(1), p. 88–91.

7. Ghio, A., Bertolotto, A., Resi, V., et al. Triglyceride metabolism in pregnancy. Adv Clin Chem, 2011, 55, p. 133–153.

8. Herrera, E., Ortega-Senovilla, H. Disturbances in lipid metabolism in diabetic pregnancy – Are these the cause of the problem? Best Pract Res Clin Endocrinol Metab, 2010, 24(4), p. 515–525.

9. Kengne, AP., Turnbull, F., MacMahon, S. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. Prog Cardiovasc Dis, 2010, 53(1), p. 45–51.

10. Kusters, DM., Homsma, SJM., Huttenk, BA., et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. Neth J Med, 2010, 68(1), p. 299–303.

11. Montes, A., Walden, CE., Knopp, RH., et al. Physiologic and supraphysiologic increases in lipoprotein lipids and apoproteins in late pregnancy and postpartum. Possible markers for the diagnosis of “prelipemia”. Arteriosclerosis, 1984, 4, p. 407–417.

12. Parikh, NI., Cnattingius, S., Dickman, PW., et al. Parity and risk of later-life maternal cardiovascular disease. Am Heart J, 2010, 159(2), p. 215–221.

13. Piechota, W., Staszewski, A. Refecence ranges of lipids and apolipoproteins in pregnancy. Europ J Obstet Gynecol Reprod Biol, 1992, 45, p. 27–35.

14. Robinson, JG., Goldberg, AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: Recommendations from the national Lipid Association Expert panel on Familial hypercholesterolemia. J Clin Lipidol, 2011, 5, p. S18–S29.

15. Rybka, J. Trnitá cesta metabolického syndromu prosadit se v praxi. Vnitř Lék, 2010, 56(7), s. 727–735.

16. Sattar, N., Greer, IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ, 2002, 325, p. 157–160.

17. Sohi, G., Revesz, A., Hardy, DB. Permanent implications of intrauterine growth restriction on cholesterol homeostasis. Semin Reprod Med, 2011, 29(3), p. 246–256.

18. Sunman, H., Canpolat, U., Sahiner, L., et al. Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia. Ann Pharmacother, 2012, 46(2), p. e5.

19. Thorogood, M., Seed, M., De Mott, K., Guideline development group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG, 2009, 116(4), p. 478–479.

20. Watts, GF., Morton, K., Jackson, P., et al. Management of patients with severe hypertriglyceridaemia during pregnancy: report of two cases with familial lipoprotein lipase deficiency. Br J Obstet Gynaecol, 1992, 99, p. 163–166.